d-pharm ltd (DPRM:Tel Aviv)
d-pharm ltd (DPRM) Snapshot
|
Open
$62.40
|
Previous Close
$62.40
|
|
|
Day High
$62.40
|
Day Low
$62.40
|
|
|
52 Week High
05/22/12 - $108.00
|
52 Week Low
12/31/12 - $53.00
|
|
|
Market Cap
30.1M
|
Average Volume 10 Days
15.2K
|
|
|
EPS TTM
$-0.23
|
Shares Outstanding
48.2M
|
|
|
EX-Date
--
|
P/E TM
--
|
|
|
Dividend
--
|
Dividend Yield
--
|
Related News
d-pharm ltd (DPRM) Related Businessweek News
No Related Businessweek News Foundd-pharm ltd (DPRM) Details
D-Pharm LTD., a biopharmaceutical company, designs and develops drugs for the treatment of brain disorders in Israel and internationally. Its products under advanced clinical development include DP-b99, a pivotal Phase III trial ongoing product in acute ischemic stroke patients; and DP-VPA, a Phase II trial completed product in epilepsy patients. The DP-b99’s therapeutic applications also include the treatment of traumatic brain injury and diminishing the risk of brain damage associated with coronary artery bypass graft surgery; and DP-VPA’s therapeutic applications comprise the treatment of bipolar disorder and prophylactic therapy in migraine patients. The company also has a pipeline of pre-clinical candidates for treatment of neuro-degenerative diseases, other CNS disorders, and cancer. Its pre-clinical candidates comprise DP-460 for the treatment of Alzheimer’s disease; DP-71 for the treatment of psoriasis; and DP-388 to treat pancreatic cancer. The company’s platform technologies, Membrane Activated Chelators and Regulated Activation of Prodrugs, enable the design of drug-candidates; and LipidoMimetix technology enables the design of analogues that mimic bioactive lipids, facilitating their use as safe and effective therapeutics. D-Pharm LTD. was founded in 1993 and is based in Rehovot, Israel.
d-pharm ltd (DPRM) Key Developments
D-Pharm Limited, Annual General Meeting, Dec 12, 2012., at 12:00 Israel Standard Time.
D-Pharm Limited, Annual General Meeting, Jun 25, 2012.
D-Pharm Limited has expanded its commercialization agreement with Wanbang Biopharmaceuticals Ltd. for D Pharm's leading product, DP-b99 for the treatment of ischemic stroke. D Pharm will receive $7.65 million in milestone payments under the expanded agreement, $1.15 million of which will be paid during 2012, in addition to the $1 million under the original agreement, signed in November 2011. The commercialization agreement was expanded to include a license for Wanbang to conduct clinical trials, licensing, marketing and sales in China for a new formulation of DP-b99 that is now under development. The drug, which has US Food and Drug Administration (FDA) Investigational New Drug (IND) designation, is currently undergoing Phase III multinational clinical study. When D Pharm receives the interim results of the Phase III study, due in February, Wanbang will pay it $650,000, and when D Pharm files its international patent for the new formulation, due in the third quarter, Wanbang will pay $500,000.
| Recently Viewed | |||
| DPRM:IT | 62.40 | 0.00 |  |
| Company | Last | Change | |
| No competitor information is available for DPRM. | |||
| View Industry Companies | |||
Industry Analysis
DPRM
Industry Average
| Valuation | DPRM | Industry Range |
| Price/Earnings | -- | Not Meaningful |
| Price/Sales | -- | Not Meaningful |
| Price/Book | -- | Not Meaningful |
| Price/Cash Flow | -- | Not Meaningful |
| TEV/Sales | -- | Not Meaningful |
Post a JobJobs
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
- New York, NY | New York UniversityPosted: Apr 19
Sponsored Financial Commentaries
Sponsored Links
To contact D-PHARM LTD, please visit www.dpharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
